Kimball ElectronicsKE
Recorded

Kimball Electronics 2027 Q1 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ1 2027Duration27 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, ladies and gentlemen, and welcome to the Kimball Electronics First Quarter Fiscal 2027 Earnings Conference Call. My name is Ina, and I will be the facilitator for today's call. All lines have been placed in listen-only mode to prevent any background noise. After the completion of the prepared remarks from the Kimball Electronics leadership team, there will be a question-and-answer period. To ask a question, simply press star, then the number 1 on your telephone keypad. Today's call, November 5, 2026, is being recorded. A replay of the call will be available on the Investor Relations page of the Kimball Electronics website. At this time, I would like to turn the call over to Mr. Andy Regrut, Vice President, Investor Relations, Strategic Development, and Treasurer. Mr. Regrut, you may begin.

Andy RegrutVP of Investor Relations, Strategic Development, and Treasurer

Thank you, and good morning, everyone. Welcome to our first quarter conference call. With me here today is Ric Phillips, our Chief Executive Officer, and Jana Croom, Chief Financial Officer. We issued a press release yesterday afternoon with our results for the first quarter of fiscal 2027, ended September 30, 2026. To accompany today's call, a presentation has been posted to the Investor Relations page on our company website. Before we get started, I'd like to remind you that we will be making forward-looking statements that involve risk and uncertainty and are subject to our safe harbor provisions as stated in our press release and SEC filings, and that actual results can differ materially from the forward-looking statements. Our commentary today will be focused on adjusted non-GAAP results. Reconciliations of GAAP to non-GAAP amounts are available in our press release.

Andy RegrutVP of Investor Relations, Strategic Development, and Treasurer

This morning, Rick will start the call with a few opening comments, Jana will review the financial results for the quarter and guidance for fiscal 2027, and Rick will complete our prepared remarks before taking your questions. I'll now turn the call over to Rick.

Ric PhillipsCEO

Thank you, Andy, and good morning, everyone. I'm encouraged by our first quarter results and solid start to fiscal 2027. Sales increased both sequentially and year-over-year, margins were healthy, and Cash Conversion Days were once again at a multi-year low. The top line benefited from organic sales growth and the contribution from Helvoet Polymer Technologies, our recent tuck-in acquisition in the medical CDMO. The organic growth was in line with expectations and driven by a high single-digit increase in medical sales. This growth aligns with our strategic focus to balance the portfolio across the verticals. Our excitement for the overall fit and growth opportunities of Helvoet are higher now than ever. With the backdrop of a strong balance sheet, we're investing in medical growth by integrating Helvoet, ramping operations in Indianapolis, leveraging our capabilities as a full-service provider, and unlocking synergies across the global footprint.

Ric PhillipsCEO

Fiscal 2027 marks an important milestone in our journey, and we are reiterating our guidance for the year, with sales expected at the high end of the range, driven by continued strength in medical. Turning now to first quarter results. Net sales for the total company were $391 million, a 5% increase on a sequential basis and up 7% when compared to Q1 of fiscal 2026. The year-over-year increase occurred in all verticals, with approximately 40% of total sales in North America and the remainder roughly split between Asia and Europe. Starting with medical, sales in Q1 totaled $116 million, a 14% increase compared to the same period a year ago and 29% of the total company.

Ric PhillipsCEO

Broad-based organic growth drove a 9% increase in the quarter, with the strength across multiple product categories, including drug delivery devices, respiratory care products, patient monitoring systems, single-use surgical instruments, and imaging systems. Industrial reported sales of $105 million, 5% higher than a year ago and 27% of total company. Similar to medical, the organic growth accounted for a meaningful portion of the increase, over one-third of it, with strength in most of the product categories, including off-highway equipment, factory automation, public safety, and smart metering. Climate control was down again this quarter, driven by lower demand for HVAC systems, primarily in North America. We're seeing new and interesting opportunities in this vertical, which could leverage our expertise in electronics manufacturing and higher level of assemblies and drive future growth. Finally, sales in automotive were $171 million, a 4% increase year-over-year and 44% of the company.

Ric PhillipsCEO

Steering drove the organic growth for us in this business, accounting for over 70% of automotive in Q1, with the ramp-up of a new program in Poland and early preparations for a transfer of production in China boosting the results. North America was sluggish once again this quarter, largely due to lower EV demand. Overall, I'm very pleased to see a return to growth and full-year sales trending to the top end of our guidance range. I'll now turn the call over to Jana for more details on the financials.

Jana CroomCFO

Jana? Thank you, and good morning, everyone.

Jana CroomCFO

As Ric highlighted, net sales in Q1 were $390.8 million, up 7% compared to last year, with 3% organic growth and $12.4 million of revenue from Helvoet, which was very close to our expectations. We expect the top line of Helvoet to ramp over the course of the fiscal year. Foreign exchange had a 1% favorable impact on consolidated sales. The gross margin rate was 7.9%, flat to last year, with favorable mix offset by higher material component costs and the ramp of our medical CDMO facility in Indianapolis. As we have called out in previous quarters, we expect this investment to continue to weigh on margins in the near term, but will improve as production increases and revenue builds. Adjusted selling and administrative expenses were $13.9 million, a $2.6 million increase year over year.

Jana CroomCFO

We continue to make investments in future growth initiatives, which include personnel costs, IT infrastructure, and the addition of Helvoet. As a reminder, in Q1 last year, we had a one-time $2 million cost recovery from a customer associated with the termination of a program. When measured as a percentage of sales, this year's rate was 3.6% versus 3.1% in Q1 fiscal 2026. Adjusted earnings before interest, taxes, depreciation, and amortization totaled $27.6 million in Q1 versus $26.7 million a year ago. Adjusted operating income was $17 million, or 4.3% of net sales, which compares to last year's adjusted operating income of $17.5 million, or 4.8% of net sales. Other income and expense was expense of $4.6 million compared to $3.5 million last year.

Jana CroomCFO

The increase this quarter was driven by higher interest as borrowing levels were elevated due to the Helvoet acquisition, which closed on the first day of the fiscal year. The effective tax rate in Q1 was 66.1% compared to 8.3% in the first quarter of last year. This year's rate was elevated by withholding taxes on cash repatriation to partially fund the acquisition of Helvoet. Last year, the Q1 rate was unusually low due to tax benefits associated with OBBA. For the full fiscal year, we're expecting the rate to be in the low 30s when excluding the impact of the withholding taxes. Adjusted net income in the first quarter was $6.1 million, or $0.25 per diluted share, compared to $12.3 million, or $0.49 a year ago.

Jana CroomCFO

The difference in the effective tax rate between the two periods accounted for 50% of the variance, approximately $0.12 per share. Turning now to the balance sheet. Cash and cash equivalents at September 30, 2026 were $72.8 million. Cash used for operating activities in the quarter was $19.3 million, with the usage driven by an inventory build needed to support future production. This was expected as we returned to growth after several quarters of declining revenue. Cash conversion days were 82 days, equaling our multi-year best from last quarter, and a one-day improvement from the first quarter of fiscal 2026. Inventory ended the quarter at $312.1 million compared to $271.9 million last quarter and $272.7 million a year ago. This quarter was approximately $40 million higher than both periods.

Jana CroomCFO

Inventory, which is classified as long-term, is not included in these totals, but it's part of the PDSOH calculation. It decreased $13.6 million in Q1. Combined, they represented a net increase of $26.7 million, but PDSOH remained at a respectable 88 days in the quarter. Capital expenditures in Q1 were $9 million, spread fairly evenly across our footprint to support future growth. Borrowings at September 30, 2026 were $235.7 million, an increase versus Q4 driven by the acquisition. Short-term liquidity available, represented as cash and cash equivalents, plus the unused portion of our credit facilities, totaled $270.8 million. We invested $3.1 million in Q1 to repurchase 127,000 shares. Since October 2015, under our board-authorized share repurchase program, a total of $118.6 million has been returned to our share owners by purchasing 7.2 million shares of common stock.

Jana CroomCFO

As Rick highlighted, we are reiterating our guidance for fiscal 2027, with sales expected at the high end of the range of $1.535 billion-$1.560 billion. Adjusted operating income is expected to be 4.4%-4.7% of net sales, and capital expenditures should be in the range of $50 million-$60 million. I will now turn the call back over to Rick.

Ric PhillipsCEO

Thanks, Jana. Before we open the lines for questions, I would like to share a few thoughts in closing. Q1 was our first quarter with Helvoet included in consolidated results, and as I mentioned in my opening remarks, our excitement for the overall strategic fit and growth opportunities of this new partnership are higher now than ever. Integration is progressing on plan and on budget as we focus on top-line synergies as a first priority. The interest levels from customers, both new and existing, are rising, particularly as the complementary capabilities of Tilburg, Pune, Indianapolis, and the broader Kimball footprint are better understood. Our enhanced medical CDMO platform is elevating our prominence in the industry as a medical device manufacturer with available capacity to support the fast-paced growth in a variety of end-market applications.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day